| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Shandong Buchang Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥16.80 |
| 52 Week High | CN¥23.30 |
| 52 Week Low | CN¥14.15 |
| Beta | 0.54 |
| 1 Month Change | -4.38% |
| 3 Month Change | 5.73% |
| 1 Year Change | -16.46% |
| 3 Year Change | -23.60% |
| 5 Year Change | -30.89% |
| Change since IPO | -64.72% |
Recent News & Updates
Shareholder Returns
| 603858 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.3% | -0.7% | -0.2% |
| 1Y | -16.5% | -15.9% | -17.8% |
Return vs Industry: 603858 matched the CN Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 603858 exceeded the CN Market which returned -17.8% over the past year.
Price Volatility
| 603858 volatility | |
|---|---|
| 603858 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 603858 has not had significant price volatility in the past 3 months.
Volatility Over Time: 603858's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 8,491 | Chao Zhao | www.buchang.com |
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. The company offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. Shandong Buchang Pharmaceuticals Co., Ltd.
Shandong Buchang Pharmaceuticals Co., Ltd. Fundamentals Summary
| 603858 fundamental statistics | |
|---|---|
| Market cap | CN¥18.64b |
| Earnings (TTM) | -CN¥2.00b |
| Revenue (TTM) | CN¥13.63b |
1.4x
P/S Ratio-9.3x
P/E RatioIs 603858 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603858 income statement (TTM) | |
|---|---|
| Revenue | CN¥13.63b |
| Cost of Revenue | CN¥4.00b |
| Gross Profit | CN¥9.63b |
| Other Expenses | CN¥11.63b |
| Earnings | -CN¥2.00b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | -1.81 |
| Gross Margin | 70.64% |
| Net Profit Margin | -14.66% |
| Debt/Equity Ratio | 26.1% |
How did 603858 perform over the long term?
See historical performance and comparison